SUBSCRIBE
SUBSCRIBE

Postmarket research

Drug Development
Heart Risk Found in Newer Antipsychotic Drugs, Vanderbilt University School of Medicine Study
January 15, 2009
 · 
1 min read
Drug Development
Epidural Risk Lower Than Thought, Bath’s Royal United Hospital Study
January 12, 2009
 · 
1 min read
Drug Development
Doctors Re-Examine Blood Thinners to Prevent Strokes, University of Cincinnati Study
January 12, 2009
 · 
1 min read
Drug Development
Heart Drug May Be a Cancer Fighter, Johns Hopkins University Study
January 8, 2009
 · 
1 min read
Drug Development
Pneumococcal Vaccine Does Not Appear To Protect Against Pneumonia, University of Bern Study
January 7, 2009
 · 
1 min read
Drug Development
Hepatitis A Vaccine Gives Long-Lasting Protection, Centers for Disease Control and Prevention (CDC) And the Alaska Native Tribal Health Consortium Researchers Report
January 7, 2009
 · 
1 min read
Drug Development
Study Raises Hope For Obesity Treatment, Harvard Medical School Study
January 7, 2009
 · 
1 min read
Drug Development
Old Gastrointestinal Drug Slows Aging, McGill University Researchers Say
January 7, 2009
 · 
1 min read
Drug Development
Viagra’s Other Talents: Help A ‘Signaling’ Protein Shield The Heart From High Blood Pressure Damage, Johns Hopkins University Study
January 6, 2009
 · 
1 min read
Drug Development
Antibiotics Before Infections Save Lives, University Medical Center Utrecht Study
January 2, 2009
 · 
1 min read
Load More
PRESS RELEASES
Drug Development
Roche’s Avastin Not Linked to Higher Risk of Blindness
August 14, 2015
 · 
5 min read
Drug Development
Results From First Human Clinical Study Demonstrate ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Effectively Increases The Co-Enzyme NAD+ And Is Safe
August 12, 2015
 · 
9 min read
Drug Development
Oasmia’s Paclical Does Well in Head to Head Study with Celgene’s Abraxane
August 4, 2015
 · 
5 min read
Drug Development
Takeda Announces Completion Of The Pioglitazone Post-Marketing Commitment And Submission Of Results To The European Medicines Agency, The European Medicines Agency And The PMDA
July 30, 2015
 · 
8 min read
Drug Development
AVANIR Pharmaceuticals Announces New Findings From Dementia/Alzheimer’s Disease Cohort Of PRISM II Study At Alzheimer’s Association International Conference
July 23, 2015
 · 
9 min read
Drug Development
Protein Sciences Corporation Release: New Clinical Study of Flublok Influenza Vaccine Shows That Groundbreaking Flublok Is More Effective Than The Traditional Flu Shot
June 25, 2015
 · 
4 min read
Drug Development
Egalet’s Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence At 60 Mg Dose
June 25, 2015
 · 
5 min read
Drug Development
Collegium Announces Publication of “Comparing the Effect Of Tampering On The Oral Pharmacokinetic Profiles Of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties,” In Pain Medicine
June 25, 2015
 · 
5 min read
Drug Development
Portola Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not
June 25, 2015
 · 
10 min read
Drug Development
Veloxis Pharmaceuticals A/S Release: Envarsus XR Demonstrates Differentiated Pharmacokinetic Profile Compared To Twice-Daily Prograf Or Once-Daily Astagraf XL In Stable Kidney Transplant Patients
June 24, 2015
 · 
3 min read
Drug Development
MediciNova, Inc. Announces New Article Published On MN-166 (Ibudilast) In Addiction Biology
June 16, 2015
 · 
5 min read
Drug Development
Kyowa Hakko USA, Inc. Release: Combination Setria Glutathione And L-Citrulline Supplementation Proven To Increase Post-Exercise Benefits
June 15, 2015
 · 
5 min read
Drug Development
Vernalis PLC Announces CCP-07 Starts 12 Month Stability Testing
June 11, 2015
 · 
4 min read
Drug Development
Zealand Pharma Informs Of Updates Given By Sanofi On Lyxumia And Lixilan On An IR Thematic Conference Call On Diabetes
June 9, 2015
 · 
3 min read
Drug Development
Zealand Pharma Informs That Data Presented From The ELIXA Study Establish Lyxumia As The First GLP-1 Receptor Agonist With Cardiovascular Safety Proven In A Long-Term Outcome Trial
June 9, 2015
 · 
6 min read
Drug Development
New Data Show Superiority of Eli Lilly’s Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes
June 8, 2015
 · 
10 min read
Drug Development
Zealand Pharma Announces That Sanofi Has Informed Of Results From Getgoal Duo-2, Showing Advantages Of Lyxumia Versus Rapid-Acting Insulin As Add-On To Lantus For The Treatment Of Type 2 Diabete
June 8, 2015
 · 
6 min read
Drug Development
Sanofi Announces Study Program Evaluating Toujeo In A Real-Life Setting
June 4, 2015
 · 
8 min read
Drug Development
Matinas BioPharma’s MAT9001 Meets Primary And Secondary Endpoints In First Human Trial Versus Vascepa
June 1, 2015
 · 
6 min read
Drug Development
Pharmacyclics Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers
May 28, 2015
 · 
7 min read
Load More